ENERGY-IMPACT-PARTNERS
16.3.2021 15:17:07 CET | Business Wire | Press release
The Berlin-based Greentech start-up Zolar receives a new investment and adds 10 million euro to the ongoing Series B funding round, raising the total investment of this series to 35 million euro. The new investment is lead by Energy Impact Partners, the biggest investor in the energy sector with offices in the USA and Europe headed by its managing partner Matthias Dill. Existing investors continue to support Zolar in the Series B. With the additional resources, the start-up sets the course for the expansion as a next generation green energy company, focusing on sustainable energy production and integral use of solar energy in private households. Zolar as a consumer brand, is placing customers at the center of energy production, and is driven by its mission of climate protection as a top business priority.
Energy provider of the future– The Next Generation Green Energy Company
The start-up defines five quality criteria, which represent the next generation of energy companies: decentralized renewable energy systems, green and affordable energy, customer centricity, significant reduction in customers’ carbon footprint, with an ultimate goal of carbon neutrality, as well as electrification and smart energy management. By installing a solar system on their own roof, customers are enabled to secure and allocate the main energy requirements of the household. Essential to this is the combination of electric mobility and solar energy, as well as the usage of self-generated power stored in residential batteries. The need for green and sustainably produced energy is also evident, due to rapidly increasing demands from customers. Zolar responds to this trend and offers homeowners an alternative to traditional energy companies, who continue to rely on fossil fuels.
“We find ourselves at the dawn of the solar age” explains Alex Melzer, CEO and co-founder of Zolar. “The solar sector proved to be very stable during the Covid-19 pandemic. In the past year, we have been able to grow our revenue significantly, and in 2021, we are targeting to triple installations across Germany. With the fresh 10 million, we are taking the company to the next level and The investment of Energy Impact Partners shows that investors recognise the relevance of regenerative energy. In doing so, they support us to grow quicker, accelerate revenue growth while at the same time having a positive impact on climate protection. Because ultimately what drives us all, is a livable future for all humans”, continued Melzer.
Private households become energy suppliers
In order for every household to become its own energy supplier, Zolar relies on technological platform solutions across the whole value chain. With full service digital concept, beginning with the Zolar Online Configurator, from a holistic customer journey to roof installation via the partner platform Zolar Project Center. The company intends to establish itself as a leading customer brand in the energy sector and is planning an expansion of the core business. In keeping with the requirement of an electrified household, the product portfolio will facilitate an integration of energy production, power storage and mobility.
“Zolar is one of the fastest growing energy start-ups in Germany”, added Matthias Dill, Managing Partner of Energy Impact Partners. “At Energy Impact Partners we closely monitor the transformation of the energy sector and with this investment we intend to provide ongoing support for Zolar’s goal – to become the energy provider of the future. The combination of technological state-of-the-art platforms, customer success and climate protection is a clear formula for success for us” continued Dill.
About Zolar
The Greentech start-up Zolar offers fixed-priced photovoltaic systems, which home owners can plan, compare and commission online, according to their needs. With the help of the in-house developed Zolar Online Configurator, homeowners have the possibility to adjust the components of their PV system according to their wishes, and along with this, receive an individual consultation from solar experts. Zolar’s wide network of local partner businesses carries out the installation on-site. The Berlin start-up employs around 150 employees across Germany and pursues the vision, to install solar panelling on every roof in the world, granting private households greater independence from energy supply systems. The gearing of energy production, energy storage and mobility enables the customer to design an electrified and smart household. As a next green energy company, Zolar empowers its customers to become energy suppliers within its own four walls, to neutralize their carbon footprint and to make an impact towards climate protection.
More information at: http://www.zolar.de
About Energy Impact Partners
Energy Impact Partners (EIP) is a global investment platform leading the transition to a sustainable energy future. EIP brings together entrepreneurs and the world's most forward-looking energy and industrial companies to advance innovation. With over $1.5 billion in assets under management, EIP invests globally across venture, growth, credit and infrastructure – and has a team of more than 45 professionals based in its offices in New York, San Francisco, Palm Beach, London, and Cologne.
For more information on EIP, please visit: www.energyimpactpartners.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005732/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
